Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

advax

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
In the search for an effective vaccine against the human pathogen, Listeria monocytogenes (Listeria), gold glyconanoparticles… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
There is a need for additional safe and effective human vaccine adjuvants. Advax™ is a novel adjuvant produced from semi… Expand
2014
2014
ABSTRACT Subunit vaccines against anthrax based on recombinant protective antigen (PA) potentially offer more consistent and less… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Although current HBV vaccines have an outstanding record of safety and efficacy, reduced immunogenicity is a problem in those of… Expand
Highly Cited
2013
Highly Cited
2013
ABSTRACT West Nile virus (WNV), currently the cause of a serious U.S. epidemic, is a mosquito-borne flavivirus and member of the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 4
Highly Cited
2012
Highly Cited
2012
Advax™ adjuvant is derived from inulin, a natural plant-derived polysaccharide that when crystallized in the delta polymorphic… Expand
Highly Cited
2012
Highly Cited
2012
BACKGROUND Timely vaccine supply is critical during influenza pandemics. A recombinant hemagglutinin (rHA)-based vaccine could… Expand
Highly Cited
2011
Highly Cited
2011
Background DNA-based vaccines have been safe but weakly immunogenic in humans to date. Methods and Findings We sought to… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2010
Highly Cited
2010
Advax is a polysaccharide-based adjuvant that potently stimulates vaccine immunogenicity without the increased reactogenicity… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2010
2010
Background We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3